FindTrial
Sign In

LTT462

DRUG5 trials

Sponsors

Novartis Pharma AG, Novartis Pharmaceuticals

Conditions

BRAF V600 Colorectal CancerMelanomaNon-Small Cell Lung CancerNon-Small-Cell Lung CarcinomaOther Solid TumorsOvarian NeoplasmsPreviously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma

Phase 1

A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.
TerminatedNCT02711345
Novartis PharmaceuticalsMelanoma, Non-Small-Cell Lung Carcinoma, Other Solid Tumors +1
Start: 2016-04-15End: 2018-11-21Updated: 2019-09-19
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
TerminatedNCT02974725
Novartis PharmaceuticalsMelanoma, Non-Small Cell Lung Cancer
Start: 2017-02-24End: 2024-04-24Updated: 2025-04-13
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
TerminatedNCT04294160
Novartis PharmaceuticalsBRAF V600 Colorectal Cancer
Start: 2020-07-22End: 2024-09-25Updated: 2025-12-24

Phase 2

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
Active, not recruitingNCT04417621
Novartis PharmaceuticalsMelanoma
Start: 2020-10-30End: 2027-02-02Updated: 2026-03-12
A randomized, open-label, multi-arm, two-part, phase II study to assess the efficacy and safety of multiple LXH254 combinations in patients with previously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma
Active, not recruitingCTIS2024-511934-11-00
Novartis Pharma AGPreviously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma
Start: 2021-04-27Target: 53Updated: 2025-12-11

Related Papers

A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer.
2024-09-266 citations
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in <i>NRAS</i>-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study
Journal of Clinical Oncology2023-03-2246 citations
Abstract CT197: Phase Ib study of LXH254 + trametinib (TMT) in patients (pts) with <i>NRAS</i>-mutant melanoma
Cancer Research2022-06-15
Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors.
Journal of Clinical Oncology2021-05-2066 citations
Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.
Journal of Clinical Oncology2020-05-2032 citations